Patent assignee · US · COMPANY

JANSSEN BIOTECH, INC.

401Patents
398Active
401Granted
61Portfolio score

Filing activity: Aug 27, 2004 → Aug 7, 2023 · 36 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US9216256B2 Palm activated drug delivery device Human Necessities 114 Active
US9233213B2 Palm activated drug delivery device Human Necessities 110 Active
US8226611B2 Anti-IL-6 antibodies, compositions, methods and uses Chemistry; Metallurgy 61 Active
USRE43672E1 Anti-IL-6 antibodies, compositions, methods and uses General 51 Active
US8623362B2 Anti-IL-6 antibodies Chemistry; Metallurgy 48 Active
USD678514S1 Drug delivery device General 42 Active
US7993645B2 Human anti-IL-23 antibodies, compositions, methods and uses Chemistry; Metallurgy 41 Active
US8722618B2 IL4/IL13 binding repeat proteins and uses Emerging Cross-Sectional Technologies 32 Active
US8106177B2 Nucleic acids encoding human anti-IL-23 antibodies Chemistry; Metallurgy 31 Active
US8785184B2 Differentiation of human embryonic stem cells Chemistry; Metallurgy 30 Active
USD677382S1 Drug delivery device General 30 Active
US8785185B2 Differentiation of human embryonic stem cells Chemistry; Metallurgy 29 Active
US9102737B2 Human anti-CD27 antibodies, methods and uses Chemistry; Metallurgy 26 Active
US8961967B2 Antibody Fc mutants with ablated effector functions Chemistry; Metallurgy 26 Active
US9603927B2 Combination therapies with anti-CD38 antibodies Chemistry; Metallurgy 25 Active
US8569227B2 Stabilized fibronectin domain compositions, methods and uses Chemistry; Metallurgy 22 Active
US8748356B2 Methods for use in human-adapting monoclonal antibodies Chemistry; Metallurgy 21 Active
US8580714B2 Methods of affinity maturing antibodies Chemistry; Metallurgy 21 Active
US9353181B2 Human anti-IL-23 antibodies, compositions, methods and uses Chemistry; Metallurgy 20 Active
US10138465B2 Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulators Chemistry; Metallurgy 19 Active
US8221760B2 Methods of treatment using human anti-IL-23 antibodies Chemistry; Metallurgy 19 Active
US9732154B2 Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia Chemistry; Metallurgy 19 Active
US9090694B2 ST2L antibody antagonists Chemistry; Metallurgy 18 Active
US9072668B2 Non-aqueous high concentration reduced viscosity suspension formulations of antibodies Chemistry; Metallurgy 18 Active
US10385135B2 Subcutaneous formulations of anti-CD38 antibodies and their uses Chemistry; Metallurgy 17 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.